cell division cycle 37 like 1, HSP90 cochaperoneGenealiases: CDC37B · HARC
Q-omics provides the consensus-scored CDC37L1 profile across patient tissues and cancer cell-line models. CDC37L1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC37L1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CDC37L1 RNA expression shows 20,274 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where CDC37L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC37L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC37L1 survival associations across molecular data types. CDC37L1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC37L1 RNA expression–survival associations across cancer types. High CDC37L1 expression shows unfavorable associations in SCLC, but favorable associations in KIRC, SKCM, LUAD, LGG and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC37L1 RNA expression.
This table summarizes CDC37L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDC37L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC37L1 shows lower tumor expression in KIRC, THCA, LUSC, BRCA, KICH and KIRP. The KIRC box plot shows higher CDC37L1 RNA expression in normal versus tumor tissue (log2 FC = −0.737, t-test p < 0.001).
This table shows molecular features associated with CDC37L1 in patient tissues and cancer cell lines. In patient samples, CDC37L1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC37L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
